Overview

Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer

Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the short-term and long-term efficacies and the safeties of pirarubicin plus docetaxel(AT group) and pirarubicin plus cyclophosphamide followed by docetaxel(AC-T group) in neoadjuvant chemotherapy of breast cancer.
Phase:
Phase 3
Details
Lead Sponsor:
307 Hospital of PLA
Treatments:
Cyclophosphamide
Docetaxel
Pirarubicin